Skip to main content

Adagrasib Dosage

Medically reviewed by Last updated on Feb 13, 2023.

Applies to the following strengths: 200 mg

Usual Adult Dose for Non-Small Cell Lung Cancer

600 mg orally twice daily

Duration of therapy: Until disease progression or unacceptable toxicity.


Use: For the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who received at least one prior treatment for their cancer.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Maximum of two dose reductions are permitted:

Permanently discontinue this drug in patients who are unable to tolerate 600 mg once daily.

Refer to manufacturer product information for full details on dose modification and management of adverse reactions.

Nausea or vomiting despite appropriate supportive care (including anti-emetic therapy):
Grade 3 or 4:

Diarrhea despite appropriate supportive care (including antidiarrheal therapy):
Grade 3 or 4:

QTc Interval Prolongation:
QTc absolute value greater than 500 ms or greater than an increase of 60 ms from baseline:

Torsade de pointes, polymorphic ventricular tachycardia or signs or symptoms of serious or life-threatening arrhythmia:

Grade 2:
Grade 3 or 4:
AST or ALT greater than 3 × ULN with total bilirubin greater than 2 × ULN in the absence of alternative causes:

Interstitial Lung Disease/Pneumonitis:
Any Grade:

Other Adverse Reactions:
Grade 3 or 4:



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:



Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.